A randomized phase II trial evaluating the addition of low dose, short course sunitinib to docetaxel in advanced solid tumours

Abstract Background We previously reported that low-dose, short-course sunitinib prior to neoadjuvant doxorubicin-cyclophosphamide (AC) normalised tumour vasculature and improved perfusion, but resulted in neutropenia and delayed subsequent cycles in breast cancer patients. This study combined sunit...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Yvonne L. E. Ang, Gwo Fuang Ho, Ross A. Soo, Raghav Sundar, Sing Huang Tan, Wei Peng Yong, Samuel G. W. Ow, Joline S. J. Lim, Wan Qin Chong, Phyu Pyar Soe, Bee Choo Tai, Lingzhi Wang, Boon Cher Goh, Soo-Chin Lee
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BMC 2020-11-01
Saila:BMC Cancer
Gaiak:
Tumour vasculature
Anti-angiogenic
Short-course sunitinib
Advanced solid tumours
Docetaxel
Sarrera elektronikoa:http://link.springer.com/article/10.1186/s12885-020-07616-4
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak